Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
The Journal of Investigative Dermatology. Symposium Proceedings|December 21, 2005
Notch and NOXA-related pathways in melanoma cellsBrian J Nickoloff, Mary J C Hendrix, Pamela M Pollock, et al.
Oncotarget|December 22, 2016
Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferationThomas Karlsson, Camilla Krakstad, Ingvild Løberg Tangen, et al.
Molecular Cancer|October 9, 2012
Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN statusSara A Byron, David C Loch, Candice L Wellens, et al.
The Journal of Pathology. Clinical Research|July 22, 2022
Spatial expression of the FGFR2b splice isoform and its prognostic significance in endometrioid endometrial carcinomaAsmerom T Sengal, Deborah Smith, Cameron E Snell, et al.
Journal of Cell Science|July 14, 2018
FGFR2-activating mutations disrupt cell polarity to potentiate migration and invasion in endometrial cancer cell modelsSamantha J Stehbens, Robert J Ju, Mark N Adams, et al.
The Journal of Biological Chemistry|October 14, 2011
Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734Andreas Wortmann, Yaowu He, Melinda E Christensen, et al.
Gynecologic Oncology|January 29, 2010
FGFR2 mutations are rare across histologic subtypes of ovarian cancerSara A Byron, Michael G Gartside, Candice L Wellens, et al.
Plos One|March 3, 2012
FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological featuresSara A Byron, Michael Gartside, Matthew A Powell, et al.
Molecular Cancer Therapeutics|January 26, 2017
PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial CancersLeisl M Packer, Xinyan Geng, Vanessa F Bonazzi, et al.
Bone Research|April 15, 2020
Correction: Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of Zoledronic acid in vivoMarietta Landgraf, Christoph A Lahr, Alvaro Sanchez-Herrero, et al.
Pageof 6